



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca/terms-of-use</u> and according to acceptable standards of care.

## **PROTOCOL CODE: HNAVPFPMB**

Page 2 of 2

DATE: To be given: Cy	cle #:
**Have Hypersensitivity Reaction Tray and Protocol Available**	
CHEMOTHERAPY:	
pembrolizumab 2 mg/kg x kg = mg (max. 200 mg)	
IV in 50 mL NS over 30 minutes using a 0.2 micron in-line filter (may be given during prehydration)	
<b>CISplatin 75 mg/m</b> <sup>2</sup> x BSA =mg	
Dose Modification:% =mg/m <sup>2</sup> x BSA =mg	
IV in NS 500 mL with potassium chloride 20 mEq, magnesium sulphate 1 g, mannitol 30 g over 1 hour	
OR CAPPOplatin ALLC 5 x (CEP $\pm$ 25) = mg	
CARBOplatin AUC 5 x (GFR + 25) =mg	
Dose Modification:% =mg	
fluorouracil 1000 mg/m²/day x BSA =mg/day for 4 days (total dose =	ma over 96 bours)
$\Box \text{ Dose Modification:} \qquad \text{mg/m}^2/\text{day x BSA} = \qquad \text{mg/day for 4 days (total dose =)}$	-
IV in D5W to a total volume of 480 mL by continuous infusion at 5 mL/h via TWO Baxter LV5 infusors (Total dose should	
be divided equally – each 240 mL over 48 hours)	
RETURN APPOINTMENT ORDERS	
Return in <b>three</b> weeks for Doctor and Cycle	
Return in 2 days for second fluorouracil infusor	
Last Cycle. Return in <b>three</b> weeks for HNAVPMBM (to continue single agent	
pembrolizumab)	
CBC & Diff, Platelets, Serum Creatinine, ALT, bilirubin, alkaline phosphatase, LDH,	
sodium, potassium, TSH prior to each cycle	
If clinically indicated: ECG Chest X-ray Serum HCG or clinically indicated child bearing potential	
☐ Free T3 and free T4 ☐ lipase ☐ morning serum cortisol	
□ serum ACTH levels □ testosterone □ estradiol □ FSH □ LH	
Glucose	
☐ Weekly nursing assessment	
□ Other tests:	
Consults:	
See general orders sheet for additional requests	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: